New triple therapy aims to control advanced liver cancer without surgery

This study tests a combination of three treatments—donafenib (a targeted drug), hepatic artery infusion chemotherapy (chemotherapy delivered directly to the liver), and sintilimab (an immunotherapy)—as the first treatment for people with unresectable hepatocellular carcinoma (liver cancer that cannot be removed by surgery). The goal is to see if this triple therapy can control the cancer longer than standard approaches. About 90 adults aged 18 to 80 who have not had prior systemic therapy for advanced disease will participate. The study is not yet recruiting.